Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication by Jiangning Liu et al.
RESEARCH Open Access
Lycorine reduces mortality of human enterovirus
71-infected mice by inhibiting virus replication
Jiangning Liu1, Yajun Yang1, Yanfeng Xu2, Chunmei Ma2, Chuan Qin1,2 and Lianfeng Zhang1,2*
Abstract
Human enterovirus 71 (EV71) infection causes hand, foot and mouth disease in children under 6 years old and this
infection occasionally induces severe neurological complications. No vaccines or drugs are clinical available to
control EV71 epidemics. In present study, we show that treatment with lycorine reduced the viral cytopathic effect
(CPE) on rhabdomyosarcoma (RD) cells by inhibiting virus replication. Analysis of this inhibitory effect of lycorine on
viral proteins synthesis suggests that lycorine blocks the elongation of the viral polyprotein during translation.
Lycorine treatment of mice challenged with a lethal dose of EV71 resulted in reduction of mortality, clinical scores
and pathological changes in the muscles of mice, which were achieved through inhibition of viral replication.
When mice were infected with a moderate dose of EV71, lycorine treatment was able to protect them from
paralysis. Lycorine may be a potential drug candidate for the clinical treatment of EV71-infected patients.
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Introduction
Human enterovirus 71 (EV71) is a positive-stranded RNA
virus belonging to the enterovirus genus of the Picornavir-
idae family [1]. EV71 infection predominantly leads to
hand, foot and mouth disease (HFMD) in children under
6 years old [2,3]. Most of the EV71 infections resolve
spontaneously; however, EV71 infection occasionally
causes neurological complications that can lead to cardio-
pulmonary failure and death [4-7]. Outbreaks of EV71
have erupted around the world in the past decades and
mainly appearing in the countries and regions of Asia in
recent years [8-10]. Hundreds of cases involving lethal
complications have been reported in each outbreak
[2,11,12], and the epidemic is still prevalent in Asia [13].
Currently, there are no vaccines or antiviral drugs avail-
able to use against EV71 infection in the clinic, and the
prevention of EV71 epidemics depends upon public sur-
veillance alone. In recent years, there have been many
efforts to develop drugs to combat EV71 infection and
dozens of drugs have been reported to show anti-EV71
activity in vitro, some of which have been evaluated in
animal models including bovine lactoferrin [14], ribavirin
[15], siRNA [16] and type I interferon [17]. Although
these drugs showed activity against EV71 infection both
in cell lines and in animal models, the clinical application
is not yet available.
Lycorine is one of the most abundant alkaloids of
Amaryllidaceae [18], and has a wide range of biological
effects including apoptotic effects on tumor cells [19],
antimalarial effects [20], anti-inflammatory effects [21]
and induction of nausea and emesis [22]. Importantly,
lycorine also has been shown to have antiviral effects on
human immunodeficiency virus (HIV-1), severe acute
respiratory syndrome-associated coronavirus (SARS-
CoV), poliovirus, coxsackie virus, measles virus, and
herpes simplex virus type 1 [23-25].
In the present study, the activity of lycorine against
EV71 replication was investigated in vitro and in mice
models infected with EV71 strain.
Materials and methods
Cells and viruses
Human rhabdomyosarcoma cells (RD) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS) as previously described [26].
A clinically isolated EV71 strain FY0805 (GenBank acces-
sion no. HQ882182) and the mouse-adapted EV71 strain
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MP10 (GenBank accession no. HQ712020) derived from
FY0805 were cultured in RD cells. The virus titres were
determined using a plaque assay as described [27], and
working stocks of virus containing109 TCID50 /ml were
prepared for experiments.
Antiviral assay in RD cells
For the antiviral assay, RD cells (2 × 104 cells/well) were
plated in 96-well plates with DMEM medium lacking anti-
biotics and grown overnight to 90% confluence at 37°C.
The RD cells were then infected with 100 TCID50 of
FY0805 and cultured continually in DMEM medium con-
taining 2% FBS. The infected cells were treated with lycor-
ine (purity ≥ 98% in an HPLC assay, National institutes for
food and drug control) in a set of concentrations in saline
as 0.1, 0.5, 1, 2, 5, 10 and 20 μg/ml. The infected RD cells
were observed for CPE or harvested at eight-hour intervals
post infection to determine the number of viral RNA
copies by quantitative RT-PCR (qRT-PCR). The half maxi-
mal inhibitory concentration (IC50) was defined as the
concentration of lycorine that caused a 50% CPE reduction
compared to that of the saline-treated control [14].
Cytotoxicity Assay
The concentration of lycorine that was required for 50%
cell cytotoxicity (CC50) was determined in RD cells as
described previously [28]. Briefly, RD cells were plated in
96-well plates and grown overnight to 90% confluence at
37°C. The cells were then treated with lycorine for 72
hours at 37°C in a set of concentrations between 1 and
200 μg/ml. CC50 was defined as the concentration of
lycorine that caused 50% CPE of RD cells.
Viral proteins expression assay by western blotting
To assess the expression of viral proteins following lycor-
ine treatment, RD cells (2 × 104 cells/well) were plated in
96-well plates and grown overnight to 90% confluence at
37°C. The cells were then infected with 105 TCID50 of
FY0805 and cultured continually for 6 hours. The
infected cells were treated with 1 μg/ml lycorine. The
infected RD cells were harvested after washing three
times with PBS (pH 7.2, Gibco) at 0.5, 1.0 and 1.5 hours
of treatment. The harvested cells were resuspended in
20 μl of PBS and lysed with three freeze-thaw cycles and
the cell debris was then removed by centrifugation at
3,000 g for 20 minutes. The supernatants were subjected
to viral RNA and protein analysis, and the infected RD
cells treated with saline were used as control.
For western blotting assay, equal amounts of aliquots
(20 μl of supernatants) were separated by 12% SDS-
PAGE and transferred onto a nitrocellulose membrane
(Immobilon NC, Millipore France). The polyclonal
mouse antibodies against the viral peptides were
prepared in our lab (anti-P70-159 for VP2, anti-P324-443 for
VP3, anti-P566-665 for VP1, anti-P1329-1440 for 2C, anti-
P1649-1731 for 3C, and anti-P1843-1951 for 3D, 1:1000
dilution) [29]. Primary antibodies were visualised with
HRP-conjugated goat anti-mouse secondary antibodies
(Sigma) using a chemiluminescent detection system
(Santa Cruz). The bands were quantified by densitometry
using Quantity One software. The intensity of bands for
six viral proteins in the saline-treated group were used as
standards and defined as 100. The density of the bands of
viral proteins in the lycorine-treated group was compared
to their respective standards.
Determination of the viral load
qRT-PCR was used to detect the viral RNA copy num-
ber. Briefly, total RNA was isolated from cultured cells
or tissues from mice using the TRIzol reagent. The total
RNA was then reverse transcribed using random hexam-
ers with a reverse-transcription kit (Promega). The
cDNA was subjected to quantitative PCR (QuantiTect
SYBR Green RT-PCR kit, QIAGEN) with a Roche Light
Cycler3.5 system for 40 cycles. The primers were EV71-
S1 (5’-AGATAGGGTGGCAGATGTAATTGAAAG-3’)
and EV71-A1 (5’- TAGCATTTGATGATGCTCCAAT
TTCAG-3’). A fragment corresponding to nucleotides
2462-2635 of FY0805 was adjusted to a concentration
gradient (1 × 101 copies/μl to 1 × 108 copies/μl) and
was used as standard to calculate the copy number of
viral RNA. Results were normalised to GAPDH.
Semi-quantitative RT-PCR was used to confirm the
results of qRT-PCR. Briefly, the viral cDNA obtained
above was assayed by PCR amplification with the same
primers, and the results were normalised to GAPDH.
Mouse protection assay
Ten- or eleven-day-old ICR mice were provided by the
Institute of Laboratory Animal Science, Peking Union
Medical College. All of the animal protocols were
approved by the institutional animal care and use commit-
tee. For lethal EV71 challenge, each ten-day-old mouse
was intraperitoneally (i.p.) inoculated with 1 × 107 TCID50
(lethal dose) of MP10. For self-limited model develop-
ment, each mouse at eleven-day-old was inoculated with 1
× 106 TCID50 of MP10 via the i.p. route. At 12 hours post
infection, the infected mice were intraperitoneally injected
with different concentrations of lycorine in saline daily
twice for 7 days. The placebo group was injected with the
same volume of saline as control. The symptoms and sur-
vival rates of infected mice were monitored daily for 2
weeks, the clinical scores were graded following previously
described standards [15] and the muscle tissues of mice
were sampled at 1 dpi, 3 dpi, 5 dpi, 7 dpi and 9 dpi and
sent for virology and pathology analysis.
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Pathology
For each experimental group, six mice were subjected to
pathologic examination. After euthanasia, the muscle
tissues were immediately immersion-fixed in 10% buffered
formalin for 48 hours. The tissues were bisected,
embedded in paraffin, and stained with hematoxylin and
eosin stain (H&E). Ten sections of muscle were observed
per animal in a blinded manner.
Immunohistochemistry
Immunohistochemistry (IHC) was used to detect virions
in the infected tissues as described previously [26].
Briefly, the sections were incubated with a monoclonal
mouse antibody for VP1 of EV71 (Millipore, 1:200 dilu-
tion) for 1 hour at 37°C. The sections were then washed
three times with PBS and incubated with HRP-conju-
gated goat anti-mouse IgG (1:5000 dilution, Sigma) for 1
hour at 37°C. The sections were developed with 3-3’dia-
minobenzidine (DAB) and observed under a light micro-
scope (Olympus).
Statistics
All data are expressed as the mean ± SD. The statistical
significance of differences in mean values was assessed by
Duncan’s multiple-range test following a one-way analy-
sis of variance (ANOVA), and survival rates were ana-
lysed by Kaplan-Meier analysis. A P value of < 0.05 was
considered to be significant.
Results
Lycorine inhibits EV71 infection in RD cells
The anti-EV71 efficacy of lycorine was tested on a
human muscular (RD) cell line in a plaque reduction
assay. As a positive control, the IC50 of ribavirin was
determined in present study and was 60 μg/ml [15].
Similarly, lycorine inhibited EV71 infection of RD cells
in a dose-dependent manner with an IC50 of 0.48 μg/ml
(Figure 1A). And the replication of EV71 (Figure 1B)
and majorities of the CPE in RD cells (Figure 1C) were
significantly inhibited by treatment with 1.0 μg/ml lycor-
ine. The CC50 of lycorine (48.5 μg/ml, Figure 2) on RD
Figure 1 The inhibition effect of lycorine on RD cells. A, IC50 of lycorine for inhibiting EV71 infection was determined by the reduction of
CPE on RD cells. B, the viral copy number was detected by qRT-PCR in the RD cells treated with lycorine at a dose of 1 μg/ml. The data are
expressed as mean values of three independent experiments ± SD, *: p < 0.05. C, CPE of EV71-infected RD cells at 3 dpi were observed under
light microscope (100×).
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cells was approximately 100-fold higher than the IC50 of
it against EV71 infection.
Lycorine blocked the elongation of the viral polyprotein
during translation
To study the inhibitory mechanism of lycorine against
EV71 infection, the synthesis of several typical viral pro-
teins were detected by western blotting in 1.5 hours peri-
ods following lycorine treatment, when the effects of
inhibition was just appeared (Figure 3A and 3B). VP2,
VP3, VP1, 2C, 3C and 3D were sequentially translated
from N-terminal to C-terminal of the viral polyprotein
during viral proteins synthesis. The band densities of these
proteins at 1.0 hour of saline-treatment were set as 100.
Then the densities of these proteins at 1.0 hour of lycor-
ine-treatment were compared with that of saline-treat-
ment respectively (Figure 3B and 3C). The inhibition of
lycorine on synthesis of C terminal proteins was more
remarkable than that of N terminal proteins, as the inhibi-
tory rate of VP2 was 12.7%, whereas that of 3D was 66.5%.
This result suggested that lycorine affected the elongation
of the viral polyprotein during translation.
Lycorine reduced the mortality of mice upon lethal EV71
challenge
We utilized the mouse model of lethal EV71 infection to
evaluate the effect of lycorine on inhibiting EV71 infection.
The placebo-treated mice developed paralysis at 3 dpi and
all of them died within 10 dpi, and treatment with riba-
virin (50 mg/kg body weight) enhanced the survival rate of
infected-mice to 12%. Meanwhile, the lycorine-treatment
at doses of 0.1 mg/kg prolonged the survival time of mice;
while the treatment at doses of 0.4 or 1.0 mg/kg enhanced
the survival rates of mice to 45% respectively (Figure 4A).
Figure 2 Determination of the CC50 of lycorine on RD cells. The
RD cells were seeded into the 96-well plate and culture for 24
hours. Lycorine with different concentrations were added in the
wells and cultured continually for 3 days. The CC50 was calculated
by the CPE of RD cells. The data are expressed as mean values of
three independent experiments.
Figure 3 Lycorine inhibited the elongation of EV71
polyprotein. The RD cells were cultured in 96-well plate and
infected with EV71 virus. The cells were treated with or without
lycorine (1 μg/ml) at 6 hours post infection. A, the Viral RNA copies
in RD cells were determined by qRT-PCR in a 0.5 hour intervals for
1.5 hours of treatment and the early stage of lycorine inhibition for
virus was detected (*: p < 0.05); B, in the early stage of virus
inhibition (0.5, 1.0 and 1.5 hours of lycorine treatment), the amounts
of viral proteins in infected RD cells was detected by western
blotting with the specific primary antibodies against different viral
proteins. C, the intensity of bands of viral proteins in control cells
were defined as 100, and the intensity of bands of viral proteins in
lycorine-treated cells were compared respectively with those of
saline-treated cells at 1 hour of treatment. These data are expressed
as mean values of three independent experiments ± SD.
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This result revealed that 0.4 mg/kg was a proper dosage
and this dosage was used to analysis the effect of lycorine
against EV71 in the further experiments.
The clinical scores of infected mice treated with pla-
cebo or lycorine (0.4 mg/kg) were systematically evalu-
ated. Treatment with lycorine delayed the paralysis
appearance to 1 day later compared with that of the pla-
cebo. And the surviving mice (45%) in the lycorine group
were completely recovered within 14 dpi (Figure 4B and
4C), while all of the mice in the placebo group were died
within 10 dpi. Consistent with the results of the clinical
scores and survival rates, virus replication in the muscle
of lycorine-treated mice were inhibited by 10-100 folds at
different time points compared to that of the saline con-
trol as detected by qRT-PCR and semi-quantitative RT-
PCR (Figure 5A and 5B). Lycorine treatment also
obviously reduced the amount of virions in muscle tis-
sues compared to the saline control by immunohistologi-
cal staining (Figure 6A). In the saline-treated group,
serious muscle necrotic appeared at 3 dpi and lead to
paralysis of mice, while the lycorine-treatment (0.4 mg/
kg) obviously reduced the muscle damage caused by
EV71 infection (Figure 6B, moderate inflammation were
observed in the muscle tissues of lycorine treated mice at
3 dpi and 9 dpi, contrast to the necrotising myositis of
placebo-treated mice from 3 dpi to 9 dpi).
Lycorine treatment protected mice from apparent
symptoms post non-lethal dose EV71 challenge
The mouse model with lethal-dose EV71 infection was
used to imitate the severe complications of EV71 infected
patients. However, as most of the EV71 infection in
patients leads to symptoms resolves spontaneously [13],
we also explored the effect of lycorine against a moderate
dose of MP10 infection in mice, which was supposed to
imitate the self limited patients. The virus replication in
muscle tissues of lycorine-treated (0.4 mg/kg) mice was
significantly inhibited by more than 100-fold compared
to the saline control as detected by qRT-PCR and semi-
quantitative RT-PCR (Figure 7A and 7B). The saline-
treated mice developed transient ruffled hair and paraly-
sis and recovered within 8 days. The lycorine treatment
protected the infected-mice from symptoms of paralysis
except occasionally skin fur (Figure 7C and 7D). These
results indicated that lycorine treatment was able to com-
pletely protect the mice from obviously symptoms upon a
low-dose EV71 challenge.
Discussion
Along with its broad biological activities and capacity to
inhibit the replication of many different viruses, we con-
firmed that lycorine can inhibit EV71 infection. Lycorine
showed inhibitory activity against EV71 replication in
RD cells, and lycorine treatment significantly enhanced
Figure 4 Lycorine treatment reduced the mortality of EV71-
infected mice. A, survival rates of the EV71 infected mice treated
with placebo, ribavirin and lycorine (three different doses) were
recorded to14 dpi (n = 40). *: p < 0.05, **: p < 0.001 (Survival rate of
the mouse after 0.4 mg/kg lycorine treatment compared to that of
the placebo). B, the clinical scores of infected-mice treated with
placebo or lycorine (0.4 mg/kg) was systematically evaluated in an
independent experiment (n = 40). *, p < 0.05. C, photos were a
typical phenotype of ruffled hair and paralysis of hind limbs caused
by EV71 infection at 8 dpi (left panel, indicated by arrow) and the
phenotype was prevented by the lycorine treatment (right panel).
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the survival rate of EV71-infected mice, which demon-
strates that lycorine may be a potential drug candidate
for the clinical treatment of EV71 infection-induced
diseases.
Previous studies indicated that lycorine can inhibit
protein synthesis in eukaryotic cells [30,31] and in cell-
free systems in which protein synthesis is catalysed by
eukaryotic ribosomes [32]. However, there have debates
on which step of protein synthesis is blocked by lycor-
ine. Jimenez et al. has indicated that lycorine halts pro-
tein synthesis in eukaryotic cells by blocking the peptide
bond formation [31]. Lycorine was shown to prevent the
coupling of the N-acetyl leucyl residue from UACCA-
acetyl leucine to puromycin, and it was therefore postu-
lated that these compounds inhibited the transpeptida-
tion reaction [32]. In contrast, it has been reported that
lycorine affects the termination but not the elongation
nor the cleavage of the polyprotein [33]. The single
large coding region of the EV71 genome is flanked by 5’
and 3’ untranslated regions (5’ and 3’ UTR). The coding
region is translated as a single polyprotein, which is
then processed by viral proteases to yield mature viral
proteins including the capsid proteins (VP1-VP4) and
non-structural proteins (2A-2C and 3A-3D) [34]. We
investigated the inhibitory mechanism of lycorine on
EV71 replication by detecting the step of the viral life
cycle that was initially blocked post drug treatment and
found that the repression effect of lycorine on the synth-
esis of viral proteins located at C terminal of the poly-
protein was earlier and more substantial than its effect
on viral proteins located at N terminal of polyprotein
(Figure 3); therefore, we concluded that the drug inhi-
bits the elongation of the viral polyprotein during pro-
tein synthesis. The imbalanced synthesis of viral
proteins could interrupt the package of the virus. And
the inhibition of 3D protein could result in the reduc-
tion of replication of virus, as the 3D protein is the
RNA polymerase of EV71 [35].
In contrast to its other wide range of biological effects,
lycorine is suspected to be the source of Amaryllidaceae
poisoning in humans and animals [36]. Empirical data
from previous reports suggests that lycorine may be
responsible for symptoms such as nausea and emesis
[22]. High concentration of lycorine-induced apoptosis of
RD cells was observed in this study (Figure 2), which
indicated that lycorine is noxious to eukaryotic cells.
However, lycorine could inhibit the replication of EV71
at very low concentration and the IC50 for inhibiting
EV71 infection was approximately 100-fold lower than
the CC50 on RD cell, suggesting that it had potential
application in the clinical treatment of EV71 infection.
This assumption was verified by evaluating the antiviral
effect of lycorine in a mouse model, as the survival rate
of 0.4 mg/kg lycorine-treated mice was significantly
enhanced compared to the control mice upon lethal
EV71 infection (Figure 4A), and the alleviation of acute
symptoms and reduction of pathological changes in the
muscles of lycorine-treated mice were achieved by inhi-
biting the replication of virus (Figure 4, 5, 6). The surviv-
ing mice in the lycorine treated group recovered within
14 days. Furthermore, lycorine treatment did not cause
Figure 5 Lycorine inhibited the replication of EV71 in muscle
tissues of mice. The infected-mice were treated with placebo or
lycorine at a dose of 0.4 mg/kg. The muscle tissues were sampled
at 1 dpi, 3 dpi, 5 dpi and 9 dpi respectively (n = 8). A, the viral
replication curve were determine by qRT-PCR (*: p < 0.05). B, the
viral burden was confirmed by semi-quantitative RT-PCR.
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any obvious side effects in the mice at the tested doses
(data not shown).
Following lethal EV71 infection, the lycorine-treated
mice had a survival rate that reached 45%, while all of
the saline-treated mice were died within 14 dpi (Figure
4). In previous studies, treatment with several drug can-
didates, including ribavirin, bovine lactoferrin, siRNA
and type I interferon, were able to enhance the survival
rates of infected mice to 18%-100% [14-17]. However,
because the infection doses of virus and strains were dif-
ferent in these experiments, it is difficult to compare the
activity of these drugs, but we observed that the effi-
ciency of lycorine against EV71 infection was better
than ribavirin, as shown in IC50 determination (Figure
1A) and evaluation by a mouse model (Figure 4A).
Furthermore, as most of the EV71 infections were self-
limited and did not cause severe complications in
patients, self-resolved EV71 infection model, in which
the infected mice develop paralysis at 5 dpi and the
symptoms were basically self-limited within 8 dpi. As
we expected, lycorine treatment was able to protect the
infected-mice from paralysis symptoms by inhibiting
EV71 replication (Figure 7). Meanwhile, we found that
lycorine could also inhibit the infectivity of three other
EV71 strains (these strains were isolated from clinical
specimens from different regions of mainland China and
belong to the C4 genotype) on RD cells (data not
shown); which demonstrates that lycorine has an effec-
tive antiviral spectrum against EV71 strains prevalent in
mainland China.
Figure 6 Lycorine reduced the virus distribution and the pathological damages. The infected mice were treated with placebo or lycorine
at a dose of 0.4 mg/kg. The muscle tissues were sampled at 1 dpi, 3 dpi, 5 dpi and 9 dpi for pathological analysis. A, the virus distribution was
detected by immunohistological staining. B, the pathological changes were observed after H&E staining. The red arrows indicated virions in
tissues, the green arrows for moderate inflammation and the blue for necrotising myositis. Magnification: 100×.
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Conclusion
In summary, we have shown that lycorine is a promising
drug candidate for treating EV71 infections that has
potential application in the clinical therapy of EV71-
infected patients and that may contribute to the control
of EV71 epidemics in Asia.
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